JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Skip to the beginning of the images gallery

Prashanth Reddy V | Senior Sales Executive

+91 9063507429

[email protected]

Survanta Injection

Be the first to review this product

SURVANTA Injection is a pulmonary surfactant used for the treatment and prevention of Respiratory Distress Syndrome (RDS) in premature infants. It contains Beractant, a naturally derived surfactant that mimics the function of endogenous surfactant in the infant's lungs, helping improve breathing until the baby can produce its own surfactant.

In stock

SKU

SBSU06933

Grouped product items
Product Name	Qty
Survanta Injection - 4 ML (Inclusive of Taxable Goods)
Survanta Injection - 8 ML (Inclusive of Taxable Goods)

Request For Quote

Survanta Injection is available to buy in increments of 1

Product Description

Features:

Contains Beractant, a natural lung surfactant
Used in preterm infants with or at risk of RDS
Administered via endotracheal route
Helps stabilize lung function during critical neonatal care
Available in 4 ml and 8 ml vials
Administered only in hospitals under professional supervision

Technical Details

Technical Details
Technical Specification	Product Name: SURVANTA Injection Dosage Forms: 4 ml and 8 ml sterile intratracheal suspension Active Ingredient: Beractant (25 mg/mL phospholipids, including dipalmitoylphosphatidylcholine) Route of Administration: Intratracheal (via endotracheal tube) Indication: Prevention and treatment of neonatal Respiratory Distress Syndrome Target Group: Premature infants ≥700 g birth weight Packaging: Single-dose sterile vials Storage Conditions: Store in a refrigerator at 2°C to 8°C; protect from light Shelf Life: Refer to packaging; usually stable until expiration when stored as directed

Product Components

Survanta Injection - 4 ML: 4 ML Single Dose Vial
Survanta Injection - 8 ML: 8 ML Single Dose Vial

Product Advantages

Significantly reduces neonatal mortality and morbidity from RDS
Improves lung compliance and oxygenation
Helps in early stabilization of breathing in preterm infants
Reduces the need for mechanical ventilation and complications of respiratory failure
Mimics natural surfactant to aid alveolar expansion